(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/198980 A1

(51) International Patent Classification:
A61K 31/4725 (2006.01) *A61P 31/14* (2006.01)
A61K 31/519 (2006.01) *A61P 37/02* (2006.01)

(21) International Application Number:
PCT/IB2021/052749

(22) International Filing Date:
01 April 2021 (01.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/005,303	04 April 2020 (04.04.2020)	US
63/018,828	01 May 2020 (01.05.2020)	US
63/162,600	18 March 2021 (18.03.2021)	US
63/164,616	23 March 2021 (23.03.2021)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **CORBO, Michael**; c/o Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US). **DANTO, Spencer Ian**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **KONCZ, Tamas**; c/o Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US). **PEEVA, Elena**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **VALDEZ, Hernan**; 235 East 42nd Street, New York, New York 10017 (US). **VINCENT, Michael Steven**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **WILLIAMS, Cara Margaret May**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2021/198980 A1

(54) Title: METHODS OF TREATING CORONAVIRUS DISEASE 2019

(57) Abstract: The present invention is related to the discovery of new methods for treating the pathologic inflammatory response associated with patients infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment a therapeutically effective amount of a JAK inhibitor, a JAK/TYK inhibitor, or an IRAK4 inhibitor, or a combination thereof.